OCRA Ovarian Cancer Research Alliance Grant Number:813369 "Exploiting PARP-modulating enzymes in ovarian cancer therapy" (DSB.AD001.196)
Project areaOncologia e Immunologia (DSB.AD001)
Structure responsible for the research project
The use of PARP inhibitors (PARPi) as maintenance therapy in women with ovarian cancer has resulted in significant prolongation of disease-free survival. However, many patients do not respond to PARPi and most of that do respond eventually develop PARPi resistance, thus raising important issues about promptly identifying patients most likely to derive benefit from PARP inhibition finding new and alternative therapies for PARPi-resistant ovarian cancers. In this project we propose to develop ARH3 and PARG proteins as biomarkers of response and resistance to PARPi whose levels and activities may allow stratification of patients who are most likely to benefit from PARP inhibition and those who will not. In addition, we aim to assess the ARH3 and PARG proteins as drug targets in a subclass of PARP-resistant ovarian cancers.
Complementary and Alternative Treatment Approaches, Technology Development and/or Marker Discovery
Start date of activity
parp, ovarian, cancer
Last update: 11/12/2023